Publish date:

ASCO Live Blog: Sunday

Here are the highlights from the second full day of clinical data presentations at ASCO 2010.



) --No rest for the weary, even on Sunday, at the

American Society of Clinical Oncology

(ASCO) annual meeting underway in Chicago.

This is the second full day of clinical data presentations at ASCO 2010, highlighted by the plenary session this afternoon that will feature highly anticipated results from a phase III study of

Bristol-Myers Squibb's

(BMY) - Get Bristol-Myers Squibb Company Report

melanoma drug ipilimumab.


(CELG) - Get Celgene Corporation Report



(AMGN) - Get Amgen Inc. Report


Nektar Therapeutics

(NKTR) - Get Nektar Therapeutics Report



TheStreet Recommends



ImmunoCellular Therapeutics



Cell Therapeutics

(CTIC) - Get CTI BioPharma Corp. Report

are among the many companies also presenting clinical data today. Later tonight,




(ARQL) - Get ArQule, Inc. Report

and Celgene are holding investor events in hotels near the ASCO meeting.

Follow this live blog throughout the day for continuous updates and reports from the ASCO meeting. I'll be reporting on clinical data presentations as I see and hear them, and I'll be blogging from the hallways, exhibition hall and meeting rooms, giving you a real-time perspective on all the investor-worthy buzz. With my iPhone and some nifty software, I'll even try to bring you photos and audio for an even deeper perspective.

I welcome your comments and questions on this live blog, too, which I'll do my best to answer and publish as time permits. You can also follow my ASCO 2010 coverage on



Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.